Contribute Try STAT+ Today

Fate Therapeutics said Friday that an experimental, off-the-shelf immunotherapy made from so-called natural killer cells induced complete tumor responses in just over half of the patients with advanced lymphoma treated in an early-stage clinical trial.

The 56% complete response rate reported for the Fate cancer treatment, called FT516, is still preliminary — and assessed from just 11 patients — but it is similar to efficacy reported with other types of cell therapy. However, the durability of the response to FT516 remains an important, unanswered question.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.